EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV protease inhibitors restore amphotericin B activity against Candida

Yehia Elgammal iD, Ehab A Salama, Mohamed N Seleem

PLOS One · 2025

DOI: 10.1371/journal.pone.0324080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Yehia Elgammal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State Univer…. Hauptthemen laut MEDLINE: Amphotericin B, HIV Protease Inhibitors, Antifungal Agents, Candida auris. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare environments. While amphotericin B is one of the most powerful antifungal agents for treating Candida infections, approximately 30% of C. auris isolates demonstrate resistance to it. Thus, the development of novel antifungal therapies is vital for tackling its life-threatening infections. In this study, we identified four HIV protease inhibitors (atazanavir, saquinavir, lopinavir and ritonavir) as strong potentiators of amphotericin B against C. auris . A synergistic effect between HIV protease inhibitors and amphotericin B was observed against 15 C. auris isolates with fractional inhibitory concentration index (FICI) ranging from 0.09 to 0.50. Additionally, the combinations between HIV protease inhibitors and amphotericin B showed fungicidal effect, significantly reducing the viable cell count in the time-kill assay within 6 hours. Furthermore, the combinations inhibited biofilm formation of C. auris by 60–75% and exhibited a remarkable suppression of C. albicans hyphae. The in vivo treatment with HIV protease inhibitors combined with amphotericin B resulted in a significant reduction of C. auris colony-forming units (CFU) by 1.7–2.6 Log 10 in the C. elegans model. These findings suggest that HIV protease inhibitors, in combination with amphotericin B, are promising candidates for the development of novel antifungal drugs to treat Candida infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amphotericin BHIV Protease InhibitorsAntifungal AgentsCandida aurisCandidaBiofilmsAnimalsMicrobial Sensitivity TestsDrug SynergismCandidiasisHumansCaenorhabditis elegans

Substanzen

Amphotericin BHIV Protease InhibitorsAntifungal Agents

Autor:innen und Institutionen

  • Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
  • Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.

ORCID-Profile: Yehia Elgammal

Zitieren

APA

Elgammal, Y., Salama, E. A., & Seleem, M. N. (2025). HIV protease inhibitors restore amphotericin B activity against Candida. PLOS One. https://doi.org/10.1371/journal.pone.0324080

Vancouver

Elgammal Y, Salama EA, Seleem MN. HIV protease inhibitors restore amphotericin B activity against Candida. PLOS One. 2025. doi:10.1371/journal.pone.0324080

BibTeX
@article{Elgammal2025,
  author = {Elgammal, Yehia and Salama, Ehab A and Seleem, Mohamed N},
  title = {HIV protease inhibitors restore amphotericin B activity against Candida},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0324080}
}
Kostenlos starten →